Posted by Michael Wonder on 12 Sep 2024
Tremfya (guselkumab) receives US FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson’s leadership in inflammatory bowel disease
11 September 2024 - The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, Tremfya showed highly statistically significant rates of endoscopic remission at one year in the pivotal QUASAR program.
Johnson & Johnson today announced that the US FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis.
